TrialNature communications2026

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

April A N Rose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.